X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (78289) 78289
Newsletter (46338) 46338
Book Review (7695) 7695
Publication (4083) 4083
Conference Proceeding (2973) 2973
Newspaper Article (2726) 2726
Transcript (398) 398
Book Chapter (177) 177
Dissertation (154) 154
Magazine Article (142) 142
Trade Publication Article (43) 43
Book / eBook (20) 20
Web Resource (11) 11
Reference (10) 10
Data Set (3) 3
Government Document (2) 2
Paper (2) 2
Journal / eJournal (1) 1
Presentation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lung cancer, non-small cell (79869) 79869
cancer (51718) 51718
humans (48465) 48465
index medicus (48103) 48103
research (45366) 45366
oncology (31997) 31997
care and treatment (31258) 31258
oncology, experimental (28893) 28893
female (26813) 26813
male (26773) 26773
lung neoplasms - pathology (23035) 23035
middle aged (22951) 22951
aged (22146) 22146
carcinoma, non-small-cell lung - pathology (21003) 21003
lung cancer (20957) 20957
lung cancer, small cell (19157) 19157
chemotherapy (18784) 18784
carcinoma, non-small-cell lung - drug therapy (17625) 17625
lung neoplasms - drug therapy (17239) 17239
non-small cell lung cancer (17045) 17045
reports (15886) 15886
prognosis (15645) 15645
adult (13952) 13952
genetic aspects (12188) 12188
analysis (11806) 11806
respiratory system (11682) 11682
carcinoma, non-small-cell lung - genetics (11204) 11204
lung neoplasms - genetics (11091) 11091
metastasis (10928) 10928
neoplasm staging (10705) 10705
aged, 80 and over (9180) 9180
lung neoplasms - mortality (8977) 8977
tumors (8915) 8915
carcinoma, non-small-cell lung - mortality (8825) 8825
radiotherapy (8567) 8567
universities and colleges (8399) 8399
survival (7862) 7862
health aspects (7786) 7786
treatment outcome (7737) 7737
lung neoplasms - metabolism (7630) 7630
carcinoma, non-small-cell lung - metabolism (7499) 7499
surgery (7436) 7436
carcinoma (7160) 7160
antineoplastic agents (6924) 6924
lung neoplasms - surgery (6899) 6899
medical research (6851) 6851
apoptosis (6843) 6843
carcinoma, non-small-cell lung - surgery (6828) 6828
antimitotic agents (6758) 6758
drug therapy (6736) 6736
antineoplastic combined chemotherapy protocols - therapeutic use (6526) 6526
physical fitness (6305) 6305
cell line, tumor (6153) 6153
mutation (6021) 6021
development and progression (6010) 6010
retrospective studies (5876) 5876
medicine, experimental (5852) 5852
clinical trials (5841) 5841
expression (5797) 5797
epidermal growth factor (5663) 5663
biochemistry (5415) 5415
survival rate (5401) 5401
hematology, oncology and palliative medicine (5184) 5184
gefitinib (5161) 5161
antineoplastic agents - therapeutic use (5027) 5027
animals (5024) 5024
adenocarcinoma (5007) 5007
communicable diseases (4800) 4800
survival analysis (4734) 4734
non-small-cell lung cancer (4723) 4723
nsclc (4714) 4714
carcinoma, non-small-cell lung - radiotherapy (4697) 4697
pharmaceutical industry (4654) 4654
lung neoplasms - radiotherapy (4566) 4566
lung neoplasms - therapy (4565) 4565
diagnosis (4564) 4564
carcinoma, non-small-cell lung - therapy (4556) 4556
patient outcomes (4439) 4439
drugs (4325) 4325
cisplatin (4306) 4306
immunotherapy (4301) 4301
cell research (4261) 4261
immunohistochemistry (4182) 4182
abridged index medicus (4116) 4116
non-small cell lung carcinoma (4112) 4112
cancer therapies (4005) 4005
gene expression (3981) 3981
therapy (3904) 3904
radiology, nuclear medicine & medical imaging (3844) 3844
lung neoplasms - diagnosis (3766) 3766
carcinoma, non-small-cell lung - diagnosis (3716) 3716
patients (3706) 3706
risk factors (3702) 3702
erlotinib (3679) 3679
cell lung-cancer (3557) 3557
mice (3465) 3465
respiratory tract diseases (3422) 3422
disease-free survival (3382) 3382
radiation (3348) 3348
follow-up studies (3249) 3249
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (124423) 124423
Chinese (1564) 1564
French (1246) 1246
Japanese (926) 926
German (570) 570
Korean (265) 265
Spanish (237) 237
Polish (228) 228
Russian (160) 160
Turkish (112) 112
Italian (92) 92
Portuguese (59) 59
Czech (54) 54
Hungarian (45) 45
Dutch (20) 20
Bulgarian (16) 16
Romanian (13) 13
Danish (12) 12
Serbian (11) 11
Icelandic (9) 9
Slovak (9) 9
Finnish (8) 8
Lithuanian (8) 8
Croatian (6) 6
Norwegian (6) 6
Hebrew (5) 5
Swedish (5) 5
Belarusian (1) 1
Bosnian (1) 1
Persian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2001, Basic and clinical oncology, ISBN 0824702743, Volume 25., 535
Book
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
2005, Hematology/oncology clinics of North America, ISBN 9781416027737, Volume 19, no. 2., xii, p. 209-426
Book
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, pp. e60317 - e60317
Aberrant expression of microRNA-146a (miR-146a) has been reported to be involved in the development and progression of various types of cancers. However, its... 
SUPPRESSOR | ONCOGENESIS | RNA | MULTIDISCIPLINARY SCIENCES | CERVICAL-CANCER | INTERFERENCE | MICRORNAS | NF-KAPPA-B | FACTOR RECEPTOR | EXPRESSION | CONTRIBUTES | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | MicroRNAs - metabolism | NF-kappa B - metabolism | Receptor, Epidermal Growth Factor - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Lung - metabolism | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung - drug effects | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | MicroRNAs - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Apoptosis | Cell Movement | MicroRNA | Growth | Monoclonal antibodies | Lung cancer, Small cell | Development and progression | Lung cancer, Non-small cell | Health aspects | Cell proliferation | Laboratories | Lung | Lung cancer | Oncology | Drug delivery | Kinases | Paraffin | Cancer therapies | Metastases | Signal transduction | Cell growth | Bioindicators | Inhibition | Gefitinib | Sensitizing | NF-κB protein | Phenotypes | Cytokines | Epidermal growth factor receptors | MiRNA | Non-small cell lung carcinoma | siRNA | Breast cancer | Gene expression | Ribonucleic acid--RNA | Patients | Pathology | Signaling | Chemotherapy | Thyroid cancer | MicroRNAs | Medical prognosis | Pancreatic cancer | Cell lines | Biomarkers | Mutation | Cell migration | Cervical cancer | Tumors | Cancer | Index Medicus | Ribonucleic acid
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung | Lung cancer | Diarrhea | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Platinum | Vomiting | Comparative studies | Carboplatin | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 08/2014, Volume 111, Issue 34, pp. E3553 - E3561
MicroRNAs (miRNAs) and siRNAs have enormous potential as cancer therapeutics, but their effective delivery to most solid tumors has been difficult. Here, we... 
miR-34 | Nanotechnology | MULTIDISCIPLINARY SCIENCES | MICRORNAS | MUTANT KRAS | DELIVERY | K-RAS | MOUSE MODEL | nanotechnology | TUMOR-SUPPRESSION | INTERFERENCE | SIRNA | P53 NETWORK | PROGRESSION | MicroRNAs - therapeutic use | RNA, Small Interfering - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Lung Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | RNA, Neoplasm - metabolism | Tumor Suppressor Protein p53 - genetics | Cisplatin - administration & dosage | MAP Kinase Signaling System | Adenocarcinoma - metabolism | Nanoparticles - therapeutic use | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Gene Expression | Carcinoma, Non-Small-Cell Lung - genetics | MicroRNAs - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Mice, Transgenic | Proto-Oncogene Proteins - genetics | Combined Modality Therapy | Lung Neoplasms - therapy | Tumor Suppressor Protein p53 - deficiency | Mice, Knockout | Carcinoma, Non-Small-Cell Lung - therapy | Animals | Adenocarcinoma - therapy | RNA, Small Interfering - therapeutic use | Cell Line, Tumor | RNA, Neoplasm - genetics | Mice | MicroRNAs - genetics | Nanoparticles - administration & dosage | Mutation | RNA, Small Interfering - administration & dosage | Cancer therapies | MicroRNAs | Lung cancer | Tumors | Index Medicus | Biological Sciences | PNAS Plus
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2012, Volume 7, Issue 4, pp. e35065 - e35065
Background: Lysine specific demethylase 1 (LSD1) has been identified and biochemically characterized in epigenetics, but the pathological roles of its... 
BREAST-CANCER | HISTONE DEMETHYLASES | PROGRAMS | BIOLOGY | Immunohistochemistry | RNA, Small Interfering - genetics | Histone Demethylases - antagonists & inhibitors | Prognosis | Humans | Lung Neoplasms - metabolism | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Epithelial-Mesenchymal Transition - genetics | Histone Demethylases - genetics | Cell Movement - genetics | Adult | Female | Lung - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | Carcinoma, Non-Small-Cell Lung - genetics | Neoplasm Invasiveness | Carcinoma, Non-Small-Cell Lung - metabolism | Survival Rate | Carcinoma, Non-Small-Cell Lung - mortality | Cell Movement - drug effects | Lung - drug effects | Cell Line, Tumor | Pargyline - pharmacology | Aged | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Epigenetic inheritance | RNA | Analysis | Oncology, Experimental | Lung cancer, Small cell | Research | Lung cancer, Non-small cell | T cells | Health aspects | Cancer | Cell proliferation | Mesenchyme | Lung | Lung cancer | Biology | mRNA | Statistical methods | Metastasis | Neuroblastoma | Assaying | Cancer therapies | Nuclei | Phase transitions | Western blotting | Cell cycle | DNA methylation | Medical research | Enzymes | Statistical analysis | Cell survival | Non-small cell lung carcinoma | siRNA | Breast cancer | Gene expression | Biological assays | Patients | Medicine | Studies | Androgens | Overexpression | Lysine | Epigenetics | Nuclei (cytology) | Immunofluorescence | Pargyline | Prostate cancer | Cell migration | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article